OncoMatch/Clinical Trials/NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Is NCT05947851 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Rituximab and Nemtabrutinib for leukemia, lymphocytic, chronic, b-cell.
Treatment: Nemtabrutinib · Venetoclax · Rituximab — The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic anticancer therapy
Relapsed or refractory to at least 1 prior available therapy
Cannot have received: BCL2 inhibitor
Has received prior B-cell lymphoma 2 inhibitor(s) (BCL2i) within ≤ 12 months before randomization
Cannot have received: radiotherapy
has received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before randomization
Cannot have received: investigational agent
Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration
Lab requirements
Blood counts
adequate organ function with specimens collected within 7 days before the start of study intervention
Kidney function
adequate organ function with specimens collected within 7 days before the start of study intervention
Liver function
adequate organ function with specimens collected within 7 days before the start of study intervention
Participants with adequate organ function with specimens collected within 7 days before the start of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group ( Site 5405) · Springdale, Arkansas
- MemorialCare Health System - Long Beach Medical Center ( Site 5421) · Long Beach, California
- Memorial Hospital West ( Site 5410) · Pembroke Pines, Florida
- Oregon Health and Science University ( Site 5425) · Portland, Oregon
- Medical Oncology Associates, PS ( Site 5406) · Spokane, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify